Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis - bromocriptine - tablet - 2.5 mg

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sandoz pharmaceuticals, switzerland - bromocriptine - tablet - 2.5 mg,

Australija - engleski - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - docusate sodium, quantity: 100 mg; bisacodyl, quantity: 10 mg - suppository, moulded - excipient ingredients: macrogol 400; hard fat; propylene glycol - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) coloxyl suppositories are indicated for constipation and for evacuation of the bowel prior to an operation, or prior to x-ray or physical examination of the colon.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - atropine sulfate monohydrate, quantity: 600 microgram - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; maize starch; purified talc; magnesium stearate - for the treatment of muscarinic toxicity resulting from exposure to anticholinesterase compounds (e.g. organophosphate pesticides). atropine tablets are not as effective as i.v. atropine, which is almost always required for significant organophosphate poisoning. however atropine tablets are of value when medical assistance is not readily available, and is indicated as a short term antidote pending access to professional medical treatment. atropine tablets are not recommended for prophylaxis for pesticide poisoning. atropine does not prevent pesticide poisoning; attempts to use atropine tablets for this purpose have lead to several cases of mild atropine poisoning as well as chronic organophosphate poisoning.

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - bromocriptine mesilate - oral tablet - 2.5mg

Kanada - engleski - Health Canada

aa pharma inc - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

Kanada - engleski - Health Canada

aa pharma inc - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

american health packaging - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus 0.5 mg - sirolimus tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. in patients at low- to moderate-immunologic risk, it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration ( 2.2)]. in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level > 80%]), it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration ( 2.3), clinical studies ( 14.3)]. cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are

Singapur - engleski - HSA (Health Sciences Authority)

pharmaforte singapore pte ltd - bromocriptine mesylate eqv bromocriptine - tablet, film coated - 2.5 mg - bromocriptine mesylate eqv bromocriptine 2.5 mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

meda pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 1mg